Seleniso was successfully included in the national medical insurance directory to assist the treatment of multiple myeloma

Sinceafter being approved by the National Medical Products Administration in 2021, the original drug Selinexor has been launched in China under the name of Selinexor Tablets (XPOVIO/XPOVIO), bringing new treatment options to the majority of patients. Today, Seleniso has successfully passed a series of evaluations by the National Medical Insurance Bureau and has been officially included in the National Medical Insurance Catalog, classified as a Class B medical insurance drug. This means that from 2024, selinesol tablets will enjoy medical insurance reimbursement.

Selinexor is known in the medical community for its active ingredientSelinexor is an innovative drug specifically targeting multiple myeloma, a malignant tumor that originates in the bone marrow. It works with bortezomib and dexamethasone in combination treatment regimens for adults who have experienced at least one treatment. For patients with more complex disease who have received at least four treatments and have worsened since their last treatment, combination therapy with selinesol and dexamethasone is an option.

Selinesol's therapeutic mechanism is unique in that it works by inhibiting a protein calledExport in1 (XPO1). This protein is abnormally highly expressed in a variety of cancer cells and inhibits the function of some proteins with anti-cancer effects. By blocking XPO1, selinesol can restore the normal functions of these anti-cancer proteins, thereby inducing cancer cells to die and effectively slowing the progression of the disease.

For domestic patients, the inclusion of selinesol in medical insurance is undoubtedly good news. Although each box of selinesol is priced at more than more than 20,000 yuan, for patients who meet the conditions for medical insurance reimbursement, they will be able to enjoy a certain degree of cost reduction. This will undoubtedly reduce the financial burden on patients and enable more patients to have access to this effective treatment. However, for patients who are not eligible for medical insurance reimbursement, they still need to bear the entire cost of the drug themselves.